J&J says single dose of coronavirus vaccine 66% effective in large trial
First published on A single shot of a coronavirus vaccine developed by Johnson & Johnson protected volunteers enrolled in a sprawling, multicountry study from developing COVID-19, results disclosed by the company Friday showed. The finding is a boost to a sputtering global immunization drive, adding another effective vaccine to a mix of shots already cleared for use in dozens of nations. J&J, one of the world's largest drugmakers, expects it can produce 1 billion doses of its vaccine this year. But the results indicate vaccination was only 66% effective in preventing moderate or severe COVID-...
Source: healthcaredive.com